Clinerion Expands in Georgia
The Medison network of clinics, Tbilisi, Georgia, has joined Clinerion’s Patient Network Explorer platform, bringing their patients access to treatments and therapies.
Patients at Medison’s network of clinics will gain access to treatments and therapies by being matched to international clinical trials.
The Medison network of clinics specializes in outpatient and dental services for all social strata. The four clinics in Tbilisi, Georgia, provide medical care to over 6,000 patients each month.
The network has specialist clinical staff and is fully equipped for clinical trials. Medison currently has several trials running.
“We are very happy to have the opportunity to support more patients in Georgia via partnership with Medison,”says Ian Rentsch, CEO of Clinerion. “We look forward to drawing more trials to the country.”
Learn more at www.clinerion.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
